問卷

TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Infectious Disease

更新時間:2023-09-19

王耀東
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

19Cases

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.
  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2023-05-10 - 2025-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2023-09-30 - 2028-08-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-01-22 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-10-31 - 2026-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-02-01 - 2026-03-18

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting7Sites

Terminated1Sites

2021-06-30 - 2023-11-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2018-12-01 - 2026-03-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 2